A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.

• ClinicalTrials.gov Identifier: NCT05363774
• Recruitment Status: Recruiting
• First Posted: May 6, 2022
• Last Update Posted: November 2, 2023
• Sponsor: Novo Nordisk A/S
• Information provided by (Responsible Party): Novo Nordisk A/S

Study Description

Brief Summary:

NNC0519-0130 is a new medicine which may possibly help participants with type 2 diabetes, as it is expected to lower elevated sugar levels in the blood. The medicine may also lower the appetite. This could help reducing overweight which is often present in participants with type 2 diabetes. In this study NNC0519-0130 is given to humans for the first time. This study will be looking into how safe the new medicine NNC0519-0130 is and will measure its concentrations in the blood. Moreover, effects on blood sugar, blood fat and body weight will be tested. There are different study parts with different participants. Healthy participants (men), healthy participants (men) with high body weight and people with diabetes (men and women) take part. Single doses and multiple doses are tested and the medicine is studied as an injection or when given orally (as a tablet). The participants are invited to take part in a part of the study which will look at the effects of weekly injected doses of NNC0519-0130 taken over the course of several weeks. It is planned that participants will be given the study medicine once weekly. The dose will be increased every three weeks, if safety and tolerability allow. Participants will take up to six different dose levels. This means that the period with weekly injections of study medicine will in total last up to 18 weeks. Participants will either get the study medicine NNC0519-0130 or placebo (a 'dummy' medicine that looks like the medicines but without any active medicine). Which medicine participant gets is decided by chance. The injection of study medicine will be done by trained staff into the tissue underneath the skin of belly using a syringe and needle. The total duration of the study could last up to 25 weeks.

Condition or disease	Intervention/treatment	Phase
Healthy Volunteers (Diabetes Mellitus, Type 2)	Drug: NNC0519-0130; Drug: Placebo (NNC0519-0130)	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 114 participants
• Allocation: Randomized
• Intervention Model: Sequential Assignment
• Masking: Triple (Participant, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Doses of NNC0519-0130 in Healthy Participants and Multiple Subcutaneous and Oral Doses of NNC0519-0130 in Participants With Overweight or Obesity and Participants With Type 2 Diabetes
• Actual Study Start Date: April 20, 2022
• Estimated Primary Completion Date: March 19, 2024
• Estimated Study Completion Date: March 19, 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: Single ascending dose (SAD) part; Participants will receive up to six dose levels of subcutaneous NNC0519-0130 or matching placebo in a sequential manner with the dose increasing between cohorts.	Drug: NNC0519-0130; SAD part: Participants will receive up to six dose levels of subcutaneous NNC0519-0130 in a sequential manner with the dose increasing between cohorts. MAD part: The participants in first cohort will receive NNC0519-0130 subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels. T2D part: Participants will receive NNC0519-0130 up to two dose levels with dose escalation within the cohort. MAD QW part: Participants will receive NNC0519-0130 up to 6 dose levels.; Drug: Placebo (NNC0519-0130); SAD part: Participants will receive up to six dose levels of subcutaneous placebo (NNC0519-0130) in a sequential manner with the dose increasing between cohorts. MAD part: Participants in first cohort will receive placebo (NNC0519-0130) subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels. T2D part: Participants will receive placebo (NNC0519-0130) up to two dose levels with dose escalation within the cohort. MAD QW part: Participants will receive Placebo up to 6 dose levels.
Experimental: Multiple ascending dose (MAD) QD part; MAD QD part comprises two cohorts in participants with overweight or obesity and a cohort in participants with type 2 diabetes (T2D). The participants in first cohort will receive NNC0519-0130 or matching placebo subcutaneously up to 5 dose levels, and the participants in the second MAD QD cohort will receive NNC0519-0130 or matching placebo orally up to 5 dose levels.	Drug: NNC0519-0130; SAD part: Participants will receive up to six dose levels of subcutaneous NNC0519-0130 in a sequential manner with the dose increasing between cohorts. MAD part: The participants in first cohort will receive NNC0519-0130 subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels. T2D part: Participants will receive NNC0519-0130 up to two dose levels with dose escalation within the cohort. MAD QW part: Participants will receive NNC0519-0130 up to 6 dose levels.; Drug: Placebo (NNC0519-0130); SAD part: Participants will receive up to six dose levels of subcutaneous placebo (NNC0519-0130) in a sequential manner with the dose increasing between cohorts. MAD part: Participants in first cohort will receive placebo (NNC0519-0130) subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels. T2D part: Participants will receive placebo (NNC0519-0130) up to two dose levels with dose escalation within the cohort. MAD QW part: Participants will receive Placebo up to 6 dose levels.
Experimental: Type 2 diabetes (T2D) part; Participants will receive NNC0519-0130 or matching placebo up to 2 dose levels with dose escalation within the cohort.	Drug: NNC0519-0130; SAD part: Participants will receive up to six dose levels of subcutaneous NNC0519-0130 in a sequential manner with the dose increasing between cohorts. MAD part: The participants in first cohort will receive NNC0519-0130 subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels. T2D part: Participants will receive NNC0519-0130 up to two dose levels with dose escalation within the cohort. MAD QW part: Participants will receive NNC0519-0130 up to 6 dose levels.; Drug: Placebo (NNC0519-0130); SAD part: Participants will receive up to six dose levels of subcutaneous placebo (NNC0519-0130) in a sequential manner with the dose increasing between cohorts. MAD part: Participants in first cohort will receive placebo (NNC0519-0130) subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels. T2D part: Participants will receive placebo (NNC0519-0130) up to two dose levels with dose escalation within the cohort. MAD QW part: Participants will receive Placebo up to 6 dose levels.
Experimental: MAD QW part; MAD QW part comprises two cohorts in participants with overweight or obesity and who are otherwise generally healthy. The participants in first cohort will receive NNC0519-0130 and 2nd cohort will receive matching placebo subcutaneously up to 6 dose levels.	Drug: NNC0519-0130; SAD part: Participants will receive up to six dose levels of subcutaneous NNC0519-0130 in a sequential manner with the dose increasing between cohorts. MAD part: The participants in first cohort will receive NNC0519-0130 subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels. T2D part: Participants will receive NNC0519-0130 up to two dose levels with dose escalation within the cohort. MAD QW part: Participants will receive NNC0519-0130 up to 6 dose levels.; Drug: Placebo (NNC0519-0130); SAD part: Participants will receive up to six dose levels of subcutaneous placebo (NNC0519-0130) in a sequential manner with the dose increasing between cohorts. MAD part: Participants in first cohort will receive placebo (NNC0519-0130) subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels. T2D part: Participants will receive placebo (NNC0519-0130) up to two dose levels with dose escalation within the cohort. MAD QW part: Participants will receive Placebo up to 6 dose levels.

Outcome Measures

Primary Outcome Measures :

1. Number of treatment emergent adverse events (TEAE) in single ascending dose (SAD) part [ Time Frame: From time of dosing (day 1) until completion of the follow-up visit (assessed up to 22 days) ]
   Measured as Number of events
2. Number of treatment emergent adverse events (TEAE) in the Multiple ascending dose with daily dosing (MAD QD) subcutaneous cohort [ Time Frame: From time of dosing (day 1) until completion of the follow-up visit (assessed up to 133 days) ]
   Measured as Number of events
3. Number of treatment emergent adverse events (TEAE) in MAD QW s.c. cohort [ Time Frame: From time of first dosing (day 1) until completion of the follow-up visit (assessed up to 133 days) ]
   Measured as Number of events
4. Number of treatment emergent adverse events (TEAE) in T2D QW cohort [ Time Frame: From time of dosing (day 1) until completion of the follow-up visit (assessed up to 133 days) ]
   Measured as number of events

Secondary Outcome Measures :

1. AUC0-∞,NNC0519-0130,SD: Area under the NNC0519-0130 plasma concentration-time curve from time 0 (time of dosing) to infinity after a single dose [ Time Frame: From pre-dose (day 1) until completion of the follow-up visit (assessed up to 22 days) ]
   Measured in h*nmol/L
2. Cmax,NNC0519-0130,SD: Maximum plasma concentration of NNC0519-0130 after a single dose [ Time Frame: From pre-dose (day 1) until completion of the follow-up visit (assessed up to 22 days) ]
   Measure in nmol/L
3. Number of treatment emergent adverse events (TEAE) in the MAD QD oral cohort [ Time Frame: From time of dosing (day 1) until completion of the follow-up visit (assessed up to 112 days) ]
   Measured as Number of events
4. AUC0-24h,NNC0519-0130,SS: Area under the NNC0519-0130 plasma concentration-time curve after the last dose in each treatment period in MAD QD part [ Time Frame: From pre-dose (last dose in each treatment period) until 24 hours post-dose ]
   Measured in h*nmol/L
5. Cmax,NNC0519-0130,SS: Maximum plasma concentration of NNC0519-0130 after the last dose in each treatment period in MAD QD part [ Time Frame: From pre-dose (last dose in each treatment period) until 24 hours postdose ]
   Measured in nmol/L
6. AUC0-168h,NNC0519-0130,MD: Area under the NNC0519-0130 plasma concentration-time curve after the last dose in T2D QW cohort [ Time Frame: From pre-dose (last dose) until 168 hours post-dose ]
   Measured in h*nmol/L
7. Cmax,NNC0519-0130,MD: Maximum plasma concentration of NNC0519-0130 after the last dose in T2D QW cohort [ Time Frame: From pre-dose (last dose) until 168 hours post-dose ]
   Measured in nmol/L
8. AUC0-168h,NNC0519-0130,SS: Area under the NNC0519-0130 plasma concentration-time curve after the last dose in each treatment period in the MAD QW s.c. cohort [ Time Frame: From pre-dose (last dose in each treatment period) until 168 hours post-dose ]
   measured in h*nmol/L
9. Cmax,NNC0519-0130,SS: Maximum plasma concentration of NNC0519-0130 after the last dose in each treatment period in the MAD QW s.c. cohort [ Time Frame: From pre-dose (last dose in each treatment period) until 168 hours post-dose ]
   Measured in nmol/L

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 64 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Single ascending dose (SAD) part:
• Male aged 18-55 years (both inclusive) at screening
• Body mass index between 18.5 kilogram per meter square (kg/m^2) and 27.0 kg/m^2 (both inclusive) at screening
• Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator
• Multiple ascending dose (MAD) part (MAD QD and MAD QW):
• Male aged 18-55 years (both inclusive) at screening
• Body mass index between 25.0 kg/m^2 and 39.9 kg/m^2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator
• Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator
• Type 2 diabetes (T2D) part:
• Female of non-childbearing potential or male aged 18-64 years (both inclusive) at screening
• Body mass index between 25.0 kg/m^2 and 39.9 kg/m^2 (both inclusive) at screening
• Diagnosed with type 2 diabetes mellitus greater than or equal to (≥) 180 days before screening
• Treatment naive to antidiabetic drugs or on a stable daily dose(s) of metformin therapy (any metformin formulation any dose) greater than or equal to (>=) 60 days before screening
• Insulin naive. However, short-term insulin treatment for a maximum of 14 days before screening is allowed, as is prior insulin treatment for gestational diabetes
• HbA1c in the range of 6.5% (inclusive) and 9.5% (inclusive)

Exclusion Criteria:

• Single ascending dose (SAD) part:
• Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
• Glycosylated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 % (48 millimoles per mole (mmol/mol)) at screening
• Use of prescription medicinal products or non-prescription drugs, except routine vitamins, occasional use of paracetamol, ibuprofen, acetylsalicylic acid, and domperidon, or topical medication not reaching systemic circulation, within 14 days before screening
• Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
• Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions
• HbA1c greater than or equal to (≥) 6.5 % (48 mmol/mol) at screening
• Use of prescription medicinal products or non-prescription drugs, except routine vitamins, occasional use of paracetamol, ibuprofen, acetylsalicylic acid, and domperidon, or topical medication not reaching systemic circulation, within 14 days before screening
• Multiple ascending dose (MAD) part (MAD QD and MAD QW):
• Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
• Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions
• HbA1c greater than or equal to (≥) 6.5 % (48 mmol/mol) at screening
• Use of prescription medicinal products or non-prescription drugs, except routine vitamins, occasional use of paracetamol, ibuprofen, acetylsalicylic acid, and domperidon, or topical medication not reaching systemic circulation, within 14 days before screening
• Type 2 diabetes (T2D) part:
• Any disorder, except for conditions associated with T2D, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
• Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with diabetes mellitus)
• Current treatment with systemically effective corticosteroids, monoamine oxidase (MAO) inhibitors, systemic non-selective beta-blockers, growth hormone, non-routine vitamins or herbal products
• Current treatment with selected oral medication with a narrow therapeutic window, such as warfarin, digoxin, tricyclic antidepressants, lithium, aminophylline, theophylline and anticonvulsants

Contacts and Locations

Contacts

Contact: Novo Nordisk; (+1) 866-867-7178; clinicaltrials@novonordisk.com

Locations

Denmark

Novo Nordisk Investigational Site; Recruiting

Søborg, Denmark, 2860

Germany

Novo Nordisk Investigational Site; Recruiting

Neuss, Germany, 41460

Sponsors and Collaborators

Novo Nordisk A/S

Investigators

• Study Director: Clinical Transparency dept. 2834; Novo Nordisk A/S

More Information

• Responsible Party: Novo Nordisk A/S
• ClinicalTrials.gov Identifier: NCT05363774
• Other Study ID Numbers: NN9541-4842; 2021-004856-41 ( EudraCT Number ); U1111-1267-4254 ( Other Identifier: World Health Organization (WHO) )
• First Posted: May 6, 2022
• Last Update Posted: November 2, 2023
• Last Verified: October 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
• URL: http://novonordisk-trials.com

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases